A Structure based Serological Test for Cervical Cancer

描述（由申请人提供）： 高危型人乳头瘤病毒（HPV）血清学检测的进展 感染、低度和高度鳞状上皮内病变， 侵袭性癌症在早期发现、监测和治疗中发挥重要作用 治疗和流行病学研究。这些条件产生抗体， HPV蛋白为血清学测定提供基础。 两种HPV 肽和重组蛋白已经作为抗原进行了测试， 其局限性限制了其临床应用。 我们已经开发出一种 限制肽以模拟其同源物构象的方法 天然蛋白质中的序列。 这些模拟物的反应性 比天然蛋白质产生的抗体的肽。它们将联合收割机 具有天然敏感性的肽的方便性和稳定性 proteins. 我们建议从高风险中开发一组限制性肽 HPV对应于L1衣壳蛋白上的构象表位，E2 转录控制蛋白和E6和E7癌蛋白，并评估其 用于血清学测定的潜力。

DESCRIPTION (provided by applicant): The development of serological tests for high-risk human papillomavirus (HPV) infection, low-grade and high-grade squamous intraepithelial lesions and invasive cancer could play important roles in early detection, monitoring treatment and epidemiological studies. These conditions generate antibodies to HPV proteins providing a basis for serological assays. While both HPV peptides and recombinant proteins have been tested as antigens, various limitations have restricted their clinical usefulness. We have developed a method for constraining peptides to mimic the conformations of their cognate sequences in native proteins. These mimetics are enormously more reactive than peptides with antibodies generated by native proteins. They combine the convenience and stability of peptides with the sensititivies of native proteins. We propose to develop a set of constrained peptides from high-risk HPVs corresponding to conformational epitopes on the L1 capsid protein, the E2 transcription control protein and the E6 and E7 oncoproteins and assess their potentials for use in a serological assay.